Retention Agreements in the Biotechnology Industry
137 Contracts & Agreements
- AbbVie Inc. (4 contracts)
- AKCEA THERAPEUTICS, INC. (1)
- Akebia Therapeutics, Inc. (10)
- Alector, Inc. (1)
- Anika Therapeutics (6)
- Apellis Pharmaceuticals, Inc. (1)
- Aprea Therapeutics, Inc. (2)
- AQUINOX PHARMACEUTICALS, INC (1)
- ARDELYX, INC. (5)
- Artiva Biotherapeutics, Inc. (1)
- ATHERSYS, INC (4)
- Axcella Health Inc. (3)
- BELLICUM PHARMACEUTICALS, INC (1)
- CATALYST BIOSCIENCES, INC. (1)
- Chelsea Worldwide Inc. (1)
- Cyclacel Pharmaceuticals, Inc. (1)
- Eiger BioPharmaceuticals, Inc. (1)
- EXICURE, INC. (2)
- FIVE PRIME THERAPEUTICS INC (4)
- FS Development Corp. (1)
- Gilead Sciences (2)
- GLYCOMIMETICS INC (2)
- HERON THERAPEUTICS, INC. (10)
- Incyte (1)
- INFINITY PHARMACEUTICALS, INC. (5)
- Intrinsic Medicine, Inc. (1)
- Invitae Corp (1)
- IONIS PHARMACEUTICALS INC (1)
- Karyopharm Therapeutics Inc. (1)
- LA JOLLA PHARMACEUTICAL CO (4)
- MiMedx Group, Inc. (2)
- Minerva Neurosciences, Inc. (10)
- Moderna, Inc. (3)
- Momenta Pharmaceuticals, Inc. (4)
- Myriad Genetics, Inc. (11)
- NORTHWEST BIOTHERAPEUTICS INC (1)
- NTN BUZZTIME INC (1)
- OPGEN INC (1)
- PDL BIOPHARMA, INC. (1)
- Praxis Precision Medicines, Inc. (1)
- Relay Therapeutics, Inc. (3)
- RenovaCare, Inc. (1)
- Savara Inc (1)
- Sesen Bio, Inc. (2)
- Spring Bank Pharmaceuticals, Inc. (1)
- SpringWorks Therapeutics, Inc. (2)
- Sun BioPharma, Inc. (3)
- SUNESIS PHARMACEUTICALS INC (1)
- Surface Oncology, Inc. (1)
- Translate Bio, Inc. (2)
- TYME TECHNOLOGIES, INC. (1)
- XOMA Corp (3)
- ZIOPHARM ONCOLOGY INC (2)
- Retention Agreement, dated as of August 7, 2024, by and between the Registrant and Brian Hahn (GLYCOMIMETICS INC, Filed With SEC on November 13, 2024)
- Retention Agreement, dated as of August 7, 2024, by and between the Registrant and Harout Semerjian (GLYCOMIMETICS INC, Filed With SEC on November 13, 2024)
- Retention Agreement with Susan Horvath dated September 23, 2024 (Sun BioPharma, Inc., Filed With SEC on September 27, 2024)
- Retention Agreement with Jennifer K. Simpson dated September 23, 2024 (Sun BioPharma, Inc., Filed With SEC on September 27, 2024)
- Executive Retention Agreement effective as of June 3, 2024 between Anika Therapeutics, Inc. and Stephen Griffin (Anika Therapeutics, Filed With SEC on May 8, 2024)
- Executive Retention Agreement, dated September 27, 2021, by and between Anika Therapeutics, Inc. and Anne Nunes (Anika Therapeutics, Filed With SEC on March 15, 2024)
- February 2024 Amendment to Retention and Separation Agreement for Michel Dahan (Akebia Therapeutics, Inc., Filed With SEC on March 14, 2024)
- February 2024 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on March 14, 2024)
- Form of Retention Agreements dated February 7, 2024 (Sun BioPharma, Inc., Filed With SEC on February 13, 2024)
- Form of Retention Agreement (Invitae Corp, Filed With SEC on January 18, 2024)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Drew Deniger (ZIOPHARM ONCOLOGY INC, Filed With SEC on November 14, 2023)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Melinda Lackey (ZIOPHARM ONCOLOGY INC, Filed With SEC on November 14, 2023)
- October 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on November 8, 2023)
- July 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on August 28, 2023)
- July 2023 Amendment to Retention and Separation Agreement for Michel Dahan (Akebia Therapeutics, Inc., Filed With SEC on August 28, 2023)
- Form of May 2023 Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on August 28, 2023)
- Management Retention Agreement, dated June 16, 2023, by and between the Company and Ira Duarte (HERON THERAPEUTICS, INC., Filed With SEC on August 14, 2023)
- Management Retention Agreement, dated June 6, 2023, by and between the Company and William Forbes (HERON THERAPEUTICS, INC., Filed With SEC on August 14, 2023)
- Retention Agreement, dated May 24, 2023, among Exicure, Inc. and Joshua Miller (EXICURE, INC., Filed With SEC on August 11, 2023)
- Retention Agreement by and between the Registrant and Peter Rahmer, dated August 3, 2023 (Relay Therapeutics, Inc., Filed With SEC on August 8, 2023)
- Key Employee Retention and Restrictive Covenant Agreement dated July 5, 2023, between the Company and Doug Rice (MiMedx Group, Inc., Filed With SEC on July 5, 2023)
- Form of Retention Agreement (Surface Oncology, Inc., Filed With SEC on June 16, 2023)
- Retention and Severance Protection Agreement between the Registrant and Lawrence Bloch dated as of March 29, 2023 (INFINITY PHARMACEUTICALS, INC., Filed With SEC on May 9, 2023)
- Retention Letter Agreement between Aprea Therapeutics, Inc. and Scott M. Coiante (Aprea Therapeutics, Inc., Filed With SEC on March 30, 2023)
- Retention Letter Agreement between Aprea Therapeutics, Inc. and Gregory A. Korbel, Ph.D (Aprea Therapeutics, Inc., Filed With SEC on March 30, 2023)
- Retention and Severance Protection Agreement between the Registrant and Seth Tasker dated as of February 22, 2023 (INFINITY PHARMACEUTICALS, INC., Filed With SEC on March 28, 2023)
- Retention and Severance Protection Agreement between the Registrant and Stephane Peluso dated as of February 22, 2023 (INFINITY PHARMACEUTICALS, INC., Filed With SEC on March 28, 2023)
- Retention and Severance Protection Agreement between the Registrant and Robert Ilaria dated as of February 22, 2023 (INFINITY PHARMACEUTICALS, INC., Filed With SEC on March 28, 2023)
- Retention and Severance Protection Agreement between the Registrant and Adelene Perkins dated as of February 22, 2023 (INFINITY PHARMACEUTICALS, INC., Filed With SEC on March 28, 2023)
- Executive Retention Agreement, dated March 9, 2020, by and between Anika Therapeutics, Inc. and David Colleran (Anika Therapeutics, Filed With SEC on March 16, 2023)
- The Amended Retention and Severance Plan dated, October 25, 2022 (XOMA Corp, Filed With SEC on March 9, 2023)
- Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Paul Fehlner (Axcella Health Inc., Filed With SEC on February 17, 2023)
- Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Margaret Koziel (Axcella Health Inc., Filed With SEC on February 17, 2023)
- Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and William Hinshaw (Axcella Health Inc., Filed With SEC on February 17, 2023)
- Key Employee Retention Agreement (MiMedx Group, Inc., Filed With SEC on January 30, 2023)
- Form of Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on November 3, 2022)
- Amendment to Management Retention Agreement, dated January 14, 2020, as amended on August 8, 2022, by and between the Company and Lisa Peraza (HERON THERAPEUTICS, INC., Filed With SEC on August 9, 2022)
- Retention Agreement with David Spellman, dated June 22, 2022 (Akebia Therapeutics, Inc., Filed With SEC on August 4, 2022)
- Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Akebia Therapeutics, Inc., Filed With SEC on May 9, 2022)
- Form of Officer Retention Letter Agreement (Akebia Therapeutics, Inc., Filed With SEC on May 9, 2022)
